Pregnancy outcomes among HIV-infected women undergoing antiretroviral therapy

Open AIDS Journal

Volumn 3, Issue , 2009, Pages 8-13

  Areechokchai, Darin ^a   Bowonwatanuwong, Chureeratana ^b   Phonrat, Benjaluck ^a   Pitisuttithum, Punnee ^a   Maek a Nantawat, Wirach ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b CHONBURI HOSPITAL   (Thailand)

Author keywords

Adverse effects; Antiretroviral drugs; HIV; PMTCT; Pregnancy

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; INDINAVIR PLUS NEVIRAPINE PLUS STAVUDINE; INDINAVIR PLUS ZIDOVUDINE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NEVIRAPINE; SAQUINAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADOLESCENT; ADULT; ANEMIA; APGAR SCORE; ARTICLE; CONTROLLED STUDY; DELIVERY; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LABOR; LIVER TOXICITY; MAJOR CLINICAL STUDY; NAUSEA; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PREVALENCE; PRIORITY JOURNAL; RASH; VIRUS TRANSMISSION; VOMITING;

EID: 74349129176     PISSN: None     EISSN: 18746136     Source Type: Journal    
DOI: 10.2174/1874613600903010008     Document Type: Article

References (19)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternalinfant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173-1180 (Pubitemid 24331334)
2. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 1998; 12: F241-7. (Pubitemid 28558591)
3. Suy A, Martínez E, Coll O, et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 2006; 20: 59-66. (Pubitemid 41818115)
4. Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy results from PACTG 1022. J Acquir Immune Defic Syndr 2004; 36: 772-776 (Pubitemid 38859341)
5. Perinatal HIV Guidelines Working Group, USA. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States [monograph on the internet]. Department of Health and Human Services; 2006 [cited 2008 Sep 6]. Available from: http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf
6. Division of Acquired Immunodeficiency Syndrome, USA. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events [monograph on the internet]. National Institute of Allergy and Infectious Disease, National Institute of Health (US); 2004[cited 2008 Apr 14]. Available from: http://www.doh.gov.za/ docs/factsheets/guidelines/artguidelines04/sec4.pdf
7. World Health Organization. Interim WHO clinical staging of HIV/AIDS and HIV/AIDS case definition for surveillance: African region [monograph on the internet]. Geneva: World Health Organization; 2005 [cited 2008 Apr 14]. WHO/HIV/2005.02. Available from: http://www.who.int/hiv/pub/guidelines/ clinicalstaging.pdf
8. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41(RR-17): 1-19. Internet: www.cdc.gov/mmwr/ preview/mmwrhtml/00018871.htm [Accessed 14 April 2008].
9. Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2007; 24: CD003510. (Pubitemid 351835434)
10. Thorne C, Newell ML. Safety of agents used to prevent mother-tochild transmission of HIV: is there any cause for concern? Drug Saf 2007; 30: 203-213
11. Watts DH. Teratogenicity risk of antiretroviral therapy in pregnancy. Curr HIV/AIDS Rep 2007; 4: 135-140 (Pubitemid 47493054)
12. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIVinfected women in the United Kingdom and Ireland. AIDS 2007; 21: 1019-1026 (Pubitemid 46684333)
13. Harris NS, Fowler MG, Sansom SL, Ruffo N, Lampe MA. Use of enhanced perinatal human immunodeficiency virus surveillance methods to assess antiretroviral use and perinatal human immunodeficiency virus transmission in the United States, 1999-2001. Am J Obstet Gynecol 2007; 197(3 Suppl): S33-S41.
14. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351: 217-228 (Pubitemid 38916040)
15. Center of Disease Control and Prevention. Anemia during pregnancy in low-income women--United States, 1987. Morb Mortal Wkly Rep 1990; 39: 73-76
16. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34(Suppl 1): S21-33. (Pubitemid 37158630)
17. Shaffer N, Bulterys M, Simonds RJ. Short courses of zidovudine and perinatal transmission of HIV. N Engl J Med 1999; 340: 1042-1043
18. Patel D, Thorne C, Fiore S, Newell ML. European Collaborative Study. Does Highly Active Antiretroviral Therapy Increase the Risk of Congenital Abnormalities in HIV-Infected Women? J Acquir Immune Defic Syndr 2005; 40: 116-118
19. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral pregnancy registry interim report for 1st January 1989 to 31st January 2003[monograph on the internet]. Geneva: World Health Organization; 2005 [cited 2008 Aug 5]. Available from http:// www.apregistry.com/who.htm